Adenocarcinoma of the cervix--are there arguments for a different treatment policy?
Adenocarcinoma of the cervix may well be aetiologically, epidemiologically, and clinically different to its squamous counterpart. Overall prognosis is poorer which may relate to an increased radiation resistance or to a propensity to spread intraperitoneally. The role of neoadjuvant and adjuvant therapy is even less well defined than in squamous cancers. Future studies in carcinoma of the cervix should either be confined to one histological type, or should at least be stratified, based on whether the disease is squamous or non-squamous.
Quinn
M A
MA
Department of Gynaecological Oncology, Royal Women's Hospital, Melbourne, Australia.
D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015994:Incidence; D009367:Neoplasm Staging; D011379:Prognosis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*